A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here is one cash-producing company that excels at turning cash into shareholder value and two that may face some trouble.
Two Stocks to Sell:
Conagra (CAG)
Trailing 12-Month Free Cash Flow Margin: 7.5%
Founded in 1919 as Nebraska Consolidated Mills in Omaha, Nebraska, Conagra Brands today (NYSE: CAG) boasts a diverse portfolio of packaged foods brands that includes everything from whipped cream to jarred pickles to frozen meals.
Why Should You Dump CAG?
- Shrinking unit sales over the past two years show it’s struggled to move its products and had to rely on price increases
- Earnings per share decreased by more than its revenue over the last three years, showing each sale was less profitable
- Capital intensity has ramped up over the last year as its free cash flow margin decreased by 4.8 percentage points
Conagra is trading at $15.21 per share, or 9.1x forward P/E. Read our free research report to see why you should think twice about including CAG in your portfolio.
Supernus Pharmaceuticals (SUPN)
Trailing 12-Month Free Cash Flow Margin: 6.4%
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ: SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.
Why Does SUPN Worry Us?
- Muted 5.6% annual revenue growth over the last five years shows its demand lagged behind its healthcare peers
- Smaller revenue base of $717.2 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Free cash flow margin dropped by 14.4 percentage points over the last five years, implying the company became more capital intensive as competition picked up
At $50.68 per share, Supernus Pharmaceuticals trades at 21.9x forward P/E. Dive into our free research report to see why there are better opportunities than SUPN.
One Stock to Watch:
PTC (PTC)
Trailing 12-Month Free Cash Flow Margin: 31.1%
Originally known as Parametric Technology Corporation until its 2013 rebranding, PTC (NASDAQ: PTC) provides software that helps manufacturers design, develop, and service physical products through digital solutions for CAD, PLM, ALM, and SLM.
Why Could PTC Be a Winner?
- Prominent and differentiated software culminates in a premier gross margin of 84.2%
- Fast payback periods on sales and marketing expenses allow the company to invest heavily and onboard many customers concurrently
- Highly efficient business model is illustrated by its impressive 38% operating margin, and it turbocharged its profits by achieving some fixed cost leverage
PTC’s stock price of $134.31 implies a valuation ratio of 6.2x forward price-to-sales. Is now the time to initiate a position? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
